Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Pulmo BioTech Inc. has announced that it will ultimately receive at least $3.3 million pursuant to the license agreement contemplated by the previously announced non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. with respect to its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market.

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

Crux Biomedical receives U.S. patent for its novel vena cava filter

Crux Biomedical Inc. announced today that it was awarded a U.S. patent, (US 7,582,100 B2), for its novel vena cava filter.

22 Oct 2009

Study finds lung scintigraphy more reliable than CTA for pulmonary embolism diagnosis in pregnant patients

A medical imaging procedure known as lung scintigraphy may be more reliable than pulmonary CT angiography (CTA) for identifying or excluding pulmonary embolism (PE) in pregnant patients, according to a study published in the November issue of the American Journal of Roentgenology.

21 Oct 2009

Cook Medical launches new products for treating peripheral arterial disease

In a tour de force of new product development and introduction, Cook Medical is introducing six new products in parallel to provide better treatment options to the physicians treating the 27 million people worldwide* afflicted with some form of peripheral arterial disease (PAD) and other diseases of the circulatory system.

21 Oct 2009

Patients with severe cases of the H1N1 virus are at risk for developing severe complications

University of Michigan researchers have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli, according to a study published today in the American Journal of Roentgenology.

15 Oct 2009

Patients who are severely ill with H1N1 are at risk for developing PE, says study

Researchers utilizing computed tomography (CT) scans have found that patients with severe cases of the H1N1 virus are at risk for developing severe complications, including pulmonary emboli (PE), according to a study to be published online Oct. 14, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.

14 Oct 2009

Patient outcomes better in highly rated hospitals than others

The largest annual study of patient outcomes at each of the nation's 5,000 nonfederal hospitals found a wide gap in quality between the nation's best hospitals and all others. According to the study, issued today by HealthGrades, the leading independent healthcare ratings organization, patients at highly rated hospitals have a 52 percent lower chance of dying compared with the U.S. hospital average, a quality chasm that has persisted for the last decade even as mortality rates, in general, have declined.

13 Oct 2009

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Baylor University Medical Center at Dallas has been recognized as one of 25 hospitals in the nation achieving exemplary outcomes for surgical patient care.

1 Oct 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Cook Medical launches next-generation IVC filter delivery system for treating pulmonary embolism

Physicians can now navigate even the most tortuous anatomy with greater speed and safety with the next-generation inferior vena cava (IVC) filter delivery system introduced today by Cook Medical at TCT 2009. The release of the NavAlign™ delivery system marks the 20th anniversary of Cook’s first IVC filter and further advances the treatment of pulmonary embolism (PE), a life-threatening condition caused by blood clots in the lungs that affects thousands of Americans annually.

24 Sep 2009

African Americans at higher risk of developing potentially deadly DVT and PE than other ethnic populations

Speaking at the Venous Disease Coalition (VDC) Annual Meeting today, Dr. Garth Graham from the Office of Minority Health at the Department of Health and Human Services followed up on last year's Surgeon General's Call to Action by focusing attention on the African American population which is at significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

18 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Bextra qui tam lawsuit leads to Pfizer's whopping $2.3 billion settlement

The decision by a Pfizer sales representative in Florida to file a whistleblower ("qui tam") lawsuit in 2003 kicked off the federal and state investigations that led to Pfizer's record-breaking $2.3 billion settlement today.

3 Sep 2009

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

Optimum Lightpath chosen as telecommunications provider by Medical Arts Radiology

Optimum Lightpath(SM), a market leader in Ethernet-based communication solutions for New York metropolitan area businesses, today announced that Medical Arts Radiology, one of the largest medical imaging groups in Long Island, has selected Optimum Lightpath as its telecommunications provider.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).